Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806507 · ClinicalTrials.gov registry record
Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 45
- Enrollment target
NCT00806507: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT00806507 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00806507 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn whether different ways of viewing echocardiogram pictures along with blood tests can help to see heart-related side effects of chemotherapy and trastuzumab earlier than the usual tests.
Primary Outcome
Identification of heart-related side effects of chemotherapy and trastuzumab using echocardiogram pictures plus blood tests.
Interventions
- PROCEDURE Echocardiograms
- PROCEDURE Blood Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-08 |
What the finished NCT00806507 record still lists
NCT00806507 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Echocardiograms is the first listed.
NCT00806507 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00806507 about?
NCT00806507 is a clinical study titled "Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients". The goal of this clinical research study is to learn whether different ways of viewing echocardiogram pictures along with blood tests can help to see heart-related side effects of chemotherapy and trastuzumab earlier than the usual tests.
What is the current status of trial NCT00806507?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2008-11. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00806507?
The interventions under investigation include: Echocardiograms (PROCEDURE), Blood Test (PROCEDURE).
Who is sponsoring clinical trial NCT00806507?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia